BMBrian M. Masters

Brian M. Masters

*This is an algorithmically generated author record based on publicly available information.

Brian M. Masters has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients

    by Jeremiah D. Momper, Raman Venkataramanan, Arin S. Jantz, Diane M. Cibrik, Kelly Md Birdwell, Tk Nguyen, Brian M. Masters, Samir J. Patel

    Background: For extended-release drug formulations, effective half-life (t1/2eff) is a relevant pharmacokinetic parameter to inform dosing strategies and time to reach steady state. Tacrolimus, an immunosuppressant commonly used for the prophylaxis of organ rejection in transplant patients, is available as both immediate- and extended-release formulations. To the best of our knowledge, the t1/2eff of tacrolimus from these different formulations has not yet been assessed. The objective of this study was to characterize the t1/2eff and terminal half-life (t1/2z) of an extended-release once-daily tacrolimus formulation (LCPT) and twice-daily immediate-release tacrolimus (IR-Tac). Methods: A noncompartmental analysis of pharmacokinetic data obtained from a phase 2 study in de novo kidney transplant recipients receiving either LCPT or IR-Tac was conducted. Intensive blood sampling was performed on days 1, 7, and 14, and tacrolimus whole blood concentrations were measured using a validated liquid chromatography with tandem mass spectrometry method. T1/2eff was estimated using within-participant accumulation ratios. T1/2z was estimated by linear regression of the terminal phase of the concentration versus time profile. Results: The median accumulation ratios of LCPT and IR-Tac on day 14 were 3.18 and 2.06, respectively. The median (interquartile range; IQR) t1/2eff for LCPT at day 14 of dosing was 48.4 (37.4–77.9) hours, whereas the t1/2z was 20.3 (17.6–22.9) hours. For IR-Tac, the median (IQR) t1/2eff and t1/2z on day 14 were 12.5 (8.8–23.0) hours and 12.2 (9.2–15.7) hours, respectively. Conclusions: Consistent with its prolonged release of tacrolimus, LCPT demonstrated a higher accumulation ratio and a longer t1/2eff compared with IR-Tac. These findings underscore the pharmacokinetic differences between different drug formulations of the same moiety and may help inform dose adjustments for LCPT in kidney transplantation.


  • Survival benefit of renal transplantation in octogenarians

    by Bharath R. Ravichandran, Tracy M. Sparkes, Brian M. Masters, Beje Thomas, Moses Demehin, Jonathan S. Bromberg, Abdolreza Haririan

    Background: Elderly patients are the fastest growing population requiring renal replacement therapy. As previous studies have shown a survival benefit of kidney transplantation compared to dialysis for end‐stage renal disease, we sought to evaluate if this survival benefit extends to octogenarians.Methods: This was a single‐center retrospective cohort study of renal allograft recipients ≥80 years transplanted from 1999 to 2014 who were compared to patients listed during the same period that did not proceed to transplantation. A secondary matched group was selected from the UNOS transplant waitlist database. The primary outcome was patient survival. Secondary outcomes included graft survival and rejection incidence.Results: Thirty‐three transplanted patients were compared to 71 patients waitlisted at our center and 66 patients from the UNOS database. Patients in the study group were transplanted 20.8 ± 16.1 months after listing. Patient survival was 87.8% at 6 months and 1 year and 71.4% at 3 years. Kidney transplantation was associated with a significant decrease in the risk of death after listing (HR: 0.22, CI: 0.11‐0.45, P < .001).Conclusion: With escalating life expectancy, kidney transplantation is a suitable treatment option in eligible octogenarians.


  • Clinical outcomes of valganciclovir prophylaxis in high‐risk (D+/R−) renal transplant recipients experiencing delayed graft function

    by Sari R. Freedman, Bharath R. Ravichandran, Brian M. Masters, Jonathan S. Bromberg, Abdolreza Haririan, Kapil K. Saharia, Emily L. Heil, Tracy Sparkes

    Background: Cytomegalovirus (CMV) outcomes with valganciclovir prophylaxis in renal transplant recipients experiencing delayed graft function (DGF) are unclear.Methods: This single center, retrospective, cohort study of CMV high‐risk (D+/R− with alemtuzumab induction) deceased donor renal transplant recipients receiving valganciclovir prophylaxis assessed CMV outcomes in patients experiencing DGF (n = 72) versus those with immediate graft function (IGF; n = 66).Results: Cytomegalovirus viremia by 12 months occurred at similar rates in the IGF and DGF groups (30.3% vs 26.4%, respectively, P = 0.71) with 89.7% (35/39) of all cases classified as CMV disease. The median time to CMV viremia post transplant was day 141 and 138 in the IGF and DGF groups, respectively (P = 0.30). The incidence of biopsy‐proven acute rejection (BPAR) was higher in the DGF group (18.1% vs 4.6%, P = 0.02) with BPAR preceding CMV in only 1 patient. There was no significant difference in graft loss (1.5% vs 4.2%, P = 0.62) or patient survival (98.5% vs 95.8%, P = 0.62) at 1 year between the IGF and DGF groups, respectively.Conclusion: Valganciclovir prophylaxis in patients experiencing DGF yielded similar CMV outcomes up to 1‐year post transplant when compared to use in patients with IGF.


  • Transient Utilization of Belatacept Facilitates Renal Recovery in Liver Transplant Recipients.

    by B. Masters, T. Sparkes, M. Jason, S. Hanish, S. Ottmann, D. Klassen, D. Potosky, W. Hutson, J. LaMattina, R. Barth